BIOMAT Database Logo BIOMAT Database Logo

In vitro and in vivo antifungal activities of BMS-181184. 1992

T Oki, and M Kakushima, and M Hirano, and A Takahashi, and A Ohta, and S Masuyoshi, and M Hatori, and H Kamei
Bristol-Myers Squibb Research Institute, Bristol-Myers Squibb K.K., Tokyo, Japan.

UI MeSH Term Description Entries
D007928 Lethal Dose 50 The dose amount of poisonous or toxic substance or dose of ionizing radiation required to kill 50% of the tested population. LD50,Dose 50, Lethal
D008297 Male Males
D008813 Mice, Inbred ICR An inbred strain of mouse that is used as a general purpose research strain, for therapeutic drug testing, and for the genetic analysis of CARCINOGEN-induced COLON CANCER. Mice, Inbred ICRC,Mice, ICR,Mouse, ICR,Mouse, Inbred ICR,Mouse, Inbred ICRC,ICR Mice,ICR Mice, Inbred,ICR Mouse,ICR Mouse, Inbred,ICRC Mice, Inbred,ICRC Mouse, Inbred,Inbred ICR Mice,Inbred ICR Mouse,Inbred ICRC Mice,Inbred ICRC Mouse
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D002177 Candidiasis Infection with a fungus of the genus CANDIDA. It is usually a superficial infection of the moist areas of the body and is generally caused by CANDIDA ALBICANS. (Dorland, 27th ed) Candida Infection,Moniliasis,Candida Infections,Candidiases,Infection, Candida,Moniliases
D003453 Cryptococcosis Fungal infection caused by genus CRYPTOCOCCUS. C gattii Infection,C neoformans Infection,C. gattii Infection,C. neoformans Infection,Cryptococcus Infection,Cryptococcus Infections,Cryptococcus gattii Infection,Torulosis,Cryptococcus neoformans Infection,C gattii Infections,C neoformans Infections,C. gattii Infections,C. neoformans Infections,Cryptococcoses,Cryptococcus gattii Infections,Cryptococcus neoformans Infections,Infection, C gattii,Infection, C neoformans,Infection, C. gattii,Infection, C. neoformans,Infection, Cryptococcus,Infection, Cryptococcus gattii,Infection, Cryptococcus neoformans,Infections, C gattii,Infections, C. neoformans,Toruloses
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000903 Antibiotics, Antineoplastic Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms. Antineoplastic Antibiotics,Cytotoxic Antibiotics,Antibiotics, Cytotoxic
D000935 Antifungal Agents Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. Anti-Fungal Agents,Antifungal Agent,Fungicides, Therapeutic,Antibiotics, Antifungal,Therapeutic Fungicides,Agent, Antifungal,Anti Fungal Agents,Antifungal Antibiotics

Related Publications

T Oki, and M Kakushima, and M Hirano, and A Takahashi, and A Ohta, and S Masuyoshi, and M Hatori, and H Kamei
In vitro antifungal and fungicidal spectra of a new pradimicin derivative, BMS-181184.
February 1995, Antimicrobial agents and chemotherapy,
T Oki, and M Kakushima, and M Hirano, and A Takahashi, and A Ohta, and S Masuyoshi, and M Hatori, and H Kamei
In vitro antifungal activity of BMS-181184 against systemic isolates of Candida, Cryptococcus, and Blastomyces species.
August 1997, Diagnostic microbiology and infectious disease,
T Oki, and M Kakushima, and M Hirano, and A Takahashi, and A Ohta, and S Masuyoshi, and M Hatori, and H Kamei
Activity of pradimicin BMS-181184 against Aspergillus spp.
August 1999, International journal of antimicrobial agents,
T Oki, and M Kakushima, and M Hirano, and A Takahashi, and A Ohta, and S Masuyoshi, and M Hatori, and H Kamei
Antifungal activity of the pradimicin derivative BMS 181184 in the treatment of experimental pulmonary aspergillosis in persistently neutropenic rabbits.
September 1998, Antimicrobial agents and chemotherapy,
T Oki, and M Kakushima, and M Hirano, and A Takahashi, and A Ohta, and S Masuyoshi, and M Hatori, and H Kamei
In vitro activity of BMS-181184 compared with those of fluconazole and amphotericin B against various candida spp.
September 1996, Antimicrobial agents and chemotherapy,
T Oki, and M Kakushima, and M Hirano, and A Takahashi, and A Ohta, and S Masuyoshi, and M Hatori, and H Kamei
Cispentacin, a new antifungal antibiotic. II. In vitro and in vivo antifungal activities.
December 1989, The Journal of antibiotics,
T Oki, and M Kakushima, and M Hirano, and A Takahashi, and A Ohta, and S Masuyoshi, and M Hatori, and H Kamei
Compartmental pharmacokinetics and tissue drug distribution of the pradimicin derivative BMS 181184 in rabbits.
October 1998, Antimicrobial agents and chemotherapy,
T Oki, and M Kakushima, and M Hirano, and A Takahashi, and A Ohta, and S Masuyoshi, and M Hatori, and H Kamei
In vitro and in vivo antifungal activities of selected Cameroonian dietary spices.
February 2014, BMC complementary and alternative medicine,
T Oki, and M Kakushima, and M Hirano, and A Takahashi, and A Ohta, and S Masuyoshi, and M Hatori, and H Kamei
Antifungal activity of tamoxifen: in vitro and in vivo activities and mechanistic characterization.
August 2009, Antimicrobial agents and chemotherapy,
T Oki, and M Kakushima, and M Hirano, and A Takahashi, and A Ohta, and S Masuyoshi, and M Hatori, and H Kamei
In vitro and in vivo activities of the novel azole antifungal agent r126638.
February 2004, Antimicrobial agents and chemotherapy,
Copied contents to your clipboard!